

Pratik Choudhary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1261792/publications.pdf>

Version: 2024-02-01

156
papers

5,175
citations

117625

34
h-index

102487

66
g-index

161
all docs

161
docs citations

161
times ranked

4774
citing authors

#	ARTICLE	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	2.2	69
2	The impact of islet mass, number of transplants, and time between transplants on graft function in a national islet transplant program. <i>American Journal of Transplantation</i> , 2022, 22, 154-164.	4.7	17
3	Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta-ethnography. <i>Diabetic Medicine</i> , 2022, 39, e14678.	2.3	10
4	Time-in-range and frequency of continuous glucose monitoring: Recommendations for South Asia. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102345.	3.6	6
5	Current provision and HCP experiences of remote care delivery and diabetes technology training for people with type 1 diabetes in the UK during the COVID-19 pandemic. <i>Diabetic Medicine</i> , 2022, 39, e14755.	2.3	10
6	Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 599-608.	4.4	39
7	Hypoglycemia Subtypes in Type 1 Diabetes: An Exploration of the Hypoglycemia Fear Survey-II. <i>Diabetes Care</i> , 2022, 45, 538-546.	8.6	8
8	Association of British Clinical Diabetologists, Diabetes Technology Network UK and Association of Children's Diabetes Clinicians Survey of UK Healthcare Professional Attitudes Towards Open-Source Automated Insulin Delivery Systems. <i>Diabetes Therapy</i> , 2022, 13, 341-353.	2.5	6
9	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application. <i>BMJ Open</i> , 2022, 12, e051651.	1.9	13
10	Delivering evidence-based interventions for type 1 diabetes in the virtual world – A review of UK practice during the SARS-CoV-2 pandemic. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109777.	2.8	1
11	Altered functional connectivity during hypoglycaemia in type 1 diabetes. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1451-1462.	4.3	3
12	Characteristics of adults with type 1 diabetes and treatment-resistant problematic hypoglycaemia: a baseline analysis from the HARPdoc RCT. <i>Diabetologia</i> , 2022, 65, 936-948.	6.3	9
13	High incidence of undetected low sensor glucose events among elderly patients with type 2 diabetes more than a decade on after the ACCORD study. <i>Current Medical Research and Opinion</i> , 2022, , 1-8.	1.9	2
14	A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc). <i>Nature Communications</i> , 2022, 13, 2229.	12.8	26
15	Generation of post-meal insulin correction boluses in type 1 diabetes simulation models for in-silico clinical trials: More realistic scenarios obtained using a decision tree approach. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 221, 106862.	4.7	2
16	Glycaemic measures for 8914 adult FreeStyle Libre users during routine care, segmented by age group and observed changes during the COVID-19 pandemic. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1976-1982.	4.4	3
17	HypoMETRICS: Hypoglycaemia Measurement, Thresholds and Impact – A multi-country clinical study to define the optimal threshold and duration of sensor-detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. <i>Diabetic Medicine</i> , 2022, 39, .	2.3	11
18	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3418.	4.0	14

#	ARTICLE	IF	CITATIONS
19	Disordered eating in women with type 1 diabetes: Continuous glucose monitoring reveals the complex interactions of glycaemia, self-care behaviour and emotion. <i>Diabetic Medicine</i> , 2021, 38, e14446.	2.3	12
20	A roadmap to recovery: ABCD recommendations on risk stratification of adult patients with diabetes in the post-COVID-19 era. <i>Diabetic Medicine</i> , 2021, 38, e14462.	2.3	8
21	Hybrid closed-loop therapy: Where are we in 2021?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 655-660.	4.4	88
22	Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic. <i>Diabetic Medicine</i> , 2021, 38, e14433.	2.3	34
23	Autoreactive T cell profiles are altered following allogeneic islet transplantation with alemtuzumab induction and re-emerging phenotype is associated with graft function. <i>American Journal of Transplantation</i> , 2021, 21, 1027-1038.	4.7	5
24	The psychopathology of recurrent diabetic ketoacidosis: A case-control study. <i>Diabetic Medicine</i> , 2021, 38, e14505.	2.3	8
25	Protocol for a cluster randomised controlled trial of the DAFNE+ (Dose Adjustment For) Tj ETQq1 1 0.784314 rgBT /Overl self-management in adults with type 1 diabetes. <i>BMJ Open</i> , 2021, 11, e040438.	1.9	6
26	Letter to the editor. <i>Diabetic Medicine</i> , 2021, 38, e14546.	2.3	0
27	The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. <i>Hormone and Metabolic Research</i> , 2021, 53, 204-206.	1.5	2
28	Hypoglycaemia detection and prediction techniques: A systematic review on the latest developments. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3449.	4.0	23
29	Does nocturnal hypoglycaemia really improve quality of life?. <i>Diabetologia</i> , 2021, 64, 1893-1894.	6.3	1
30	ABCD, DTN-UK, and YDEF News. <i>British Journal of Diabetes</i> , 2021, 21, 158-168.	0.2	0
31	ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic. <i>British Journal of Diabetes</i> , 2021, 21, 123-131.	0.2	7
32	A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1989-1994.	4.4	26
33	Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time-in-ranges with the desired precision. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2446-2454.	4.4	10
34	The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond. <i>Diabetes Therapy</i> , 2021, 12, 2311-2327.	2.5	18
35	Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. <i>Diabetes Therapy</i> , 2021, 12, 2289-2310.	2.5	28
36	Personality traits of alexithymia and perfectionism in impaired awareness of hypoglycemia in adults with type 1 diabetes - An exploratory study. <i>Journal of Psychosomatic Research</i> , 2021, 150, 110634.	2.6	6

#	ARTICLE	IF	CITATIONS
37	Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit. <i>Diabetes Care</i> , 2021, 44, e190-e191.	8.6	3
38	Toward an Optimal Definition of Hypoglycemia with Continuous Glucose Monitoring. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 209, 106303.	4.7	5
39	Restoration of Hypoglycemia Awareness Alters Brain Activity in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 533-540.	8.6	6
40	A Mathematical Formula to Determine the Minimum Continuous Glucose Monitoring Duration to Assess Time-in-ranges: Sensitivity Analysis Over the Parameters. , 2021, 2021, 1435-1438.		1
41	ABCD News. <i>British Journal of Diabetes</i> , 2021, 21, 298-306.	0.2	0
42	Choosing the duration of continuous glucose monitoring for reliable assessment of time in range: A new analytical approach to overcome the limitations of correlation-based methods. <i>Diabetic Medicine</i> , 2021, , e14758.	2.3	1
43	Hypoglycemic thalamic activation in type 1 diabetes is associated with preserved symptoms despite reduced epinephrine. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 787-798.	4.3	14
44	Distal technology interventions in people with diabetes: an umbrella review of multiple health outcomes. <i>Diabetic Medicine</i> , 2020, 37, 1966-1976.	2.3	15
45	Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes. <i>Diabetologia</i> , 2020, 63, 313-323.	6.3	34
46	Treatment of type 1 diabetes complicated by problematic hypoglycemia. , 2020, , 391-406.		0
47	Characterization of pre-transplant psychosocial burden in an integrated national islet transplant program. <i>Islets</i> , 2020, 12, 21-31.	1.8	3
48	Type 1 diabetes and fasting in Ramadan: time to rethink classification of risk?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 656-658.	11.4	9
49	An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia. <i>Scientific Reports</i> , 2020, 10, 18180.	3.3	9
50	Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 681-685.	4.4	1
51	Doâ€œyourself closedâ€œloop systems for people living with type 1 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 1977-1980.	2.3	16
52	Donor insulin use predicts betaâ€œcell function after islet transplantation. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1874-1879.	4.4	6
53	Differentiating Hypoglycemia Awareness Status from Hypoglycemia Experience in Tools for Measuring Impaired Awareness of Hypoglycemia. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 541-545.	4.4	17
54	A systematic review of the effect of prior hypoglycaemia on cognitive function in type 1 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882090601.	3.2	12

#	ARTICLE	IF	CITATIONS
55	InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring Study Design. <i>Diabetes Therapy</i> , 2020, 11, 1017-1027.	2.5	15
56	Health-care professional opinions of DIY artificial pancreas systems in the UK. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 186-187.	11.4	22
57	Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better LIVEs (HypoRESOLVE) project. <i>Diabetic Medicine</i> , 2020, 37, 1066-1073.	2.3	27
58	The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 4709-4723.	5.4	19
59	Baseline Glucose Variability and Interweek Variability Affects the Time to Stability of Continuous Glucose Monitoring-Derived Glycemic Indices. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 937-942.	4.4	7
60	Supporting people with diabetes during the COVID-19 pandemic without face-to-face appointments. <i>British Journal of Diabetes</i> , 2020, 20, 1-4.	0.2	9
61	ABCD News. <i>British Journal of Diabetes</i> , 2020, 20, 172-178.	0.2	0
62	Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research: contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention. <i>Diabetic Medicine</i> , 2019, 36, 1329-1335.	2.3	23
63	Glycaemic variability: The underrecognized therapeutic target in type 1 diabetes care. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2599-2608.	4.4	33
64	Impaired Awareness of Hypoglycemia Disrupts Blood Flow to Brain Regions Involved in Arousal and Decision Making in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 2127-2135.	8.6	17
65	A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the UK. <i>Diabetic Medicine</i> , 2019, 36, 988-994.	2.3	8
66	Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK. <i>Diabetic Medicine</i> , 2019, 36, 1100-1108.	2.3	17
67	Characterization of the Effects of Mesenchymal Stromal Cells on Mouse and Human Islet Function. <i>Stem Cells Translational Medicine</i> , 2019, 8, 935-944.	3.3	17
68	Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 462-472.	11.4	84
69	A Type 1 diabetes technology pathway: consensus statement for the use of technology in Type 1 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 531-538.	2.3	29
70	Future of information technology and telecommunication in type 1 diabetes clinical care: results of an online survey. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000917.	2.8	4
71	Challenges in glucoCEST MR body imaging at 3 Tesla. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1628-1640.	2.0	21
72	Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc): protocol for a group randomised controlled trial of a novel intervention addressing cognitions. <i>BMJ Open</i> , 2019, 9, e030356.	1.9	30

#	ARTICLE	IF	CITATIONS
73	To pump or not to pump. Practical Diabetes, 2019, 36, 219-221.	0.3	0
74	Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3. Diabetes, Obesity and Metabolism, 2019, 21, 715-719.	4.4	6
75	Defining outcomes for β -cell replacement therapy in the treatment of diabetes: a consensus report on the IGLS criteria from the IPITA/EPITA opinion leaders workshop. Transplant International, 2018, 31, 343-352.	1.6	80
76	Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology. Diabetologia, 2018, 61, 761-769.	6.3	38
77	Evaluating the relationships of hypoglycaemia and HbA1c with screening-detected diabetes distress in type 1 diabetes. Endocrinology, Diabetes and Metabolism, 2018, 1, e00003.	2.4	23
78	Defining Outcomes for β -cell Replacement Therapy in the Treatment of Diabetes. Transplantation, 2018, 102, 1479-1486.	1.0	75
79	Optimal prandial timing of bolus insulin in diabetes management: a review. Diabetic Medicine, 2018, 35, 306-316.	2.3	75
80	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
81	Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 2018, 12, 634-638.	2.2	22
82	Distal technologies and type 1 diabetes management. Lancet Diabetes and Endocrinology, 2018, 6, 143-156.	11.4	49
83	Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. Diabetes Technology and Therapeutics, 2018, 20, 758-766.	4.4	7
84	Joint British Diabetes Societies for Inpatient Care: clinical guidelines and improving inpatient diabetes care. Diabetic Medicine, 2018, 35, 988-991.	2.3	16
85	The impact of hypoglycaemia awareness status on regional brain responses to acute hypoglycaemia in men with type 1 diabetes. Diabetologia, 2018, 61, 1676-1687.	6.3	16
86	Investigating the Association Between Diabetes Distress and Self-Management Behaviors. Journal of Diabetes Science and Technology, 2018, 12, 1116-1124.	2.2	15
87	Virus-like infection induces human β cell dedifferentiation. JCI Insight, 2018, 3, .	5.0	53
88	Insulin Pump Best Practice Guide from the ABCD Diabetes Technology Network UK. British Journal of Diabetes, 2018, 18, 69-70.	0.2	3
89	Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, S-55-S-61.	4.4	60
90	Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine, 2017, 34, 1456-1460.	2.3	13

#	ARTICLE	IF	CITATIONS
91	Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity. Cellular Physiology and Biochemistry, 2017, 44, 1352-1359.	1.6	21
92	Mesenchymal stromal cells improve human islet function through released products and extracellular matrix. Clinical Science, 2017, 131, 2835-2845.	4.3	55
93	Who Should Be Considered for Islet Transplantation Alone?. Current Diabetes Reports, 2017, 17, 23.	4.2	10
94	The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes, Obesity and Metabolism, 2017, 19, 257-265.	4.4	186
95	Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, 2017, 40, 63-68.	8.6	141
96	T1resources.uk; rated, reviewed, reliable. A co-created website for people affected by type 1 diabetes.. British Journal of Diabetes, 2017, 17, 111.	0.2	3
97	Report from IPITA-TTS Opinion Leaders Meeting on the Future of β -Cell Replacement. Transplantation, 2016, 100, S1-S44.	1.0	66
98	Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β -Cell Replacement. Transplantation, 2016, 100, e25-e31.	1.0	32
99	Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Diabetes Technology and Therapeutics, 2016, 18, 288-291.	4.4	107
100	Evaluation of the Effect of Carbohydrate Intake on Postprandial Glucose in Patients With Type 1 Diabetes Treated With Insulin Pumps. Journal of Diabetes Science and Technology, 2016, 10, 1287-1293.	2.2	9
101	Effectiveness of Automated Insulin Management Features of the MiniMed [®] 640G Sensor-Augmented Insulin Pump. Diabetes Technology and Therapeutics, 2016, 18, 657-663.	4.4	65
102	Acceptability of Robot Assistant in Management of Type 1 Diabetes in Children. Diabetes Technology and Therapeutics, 2016, 18, 551-554.	4.4	31
103	Implications of Predictive Low-Glucose Management System in Hybrid of Full Closed Loop System. Diabetes Technology and Therapeutics, 2016, 18, 408-409.	4.4	2
104	Hypoglycemia as a Function of HbA1c in Type 2 Diabetes (T2DM): Insulin Glargine 300 μ U/mL in a Patient-Level Meta-Analysis of EDITION 1, 2 and 3 Image 2. Canadian Journal of Diabetes, 2016, 40, S47.	0.8	0
105	First case of pancreas transplant alone in a patient with diabetes and HIV infection. International Journal of STD and AIDS, 2016, 27, 1350-1353.	1.1	4
106	Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction. BBA Clinical, 2016, 5, 143-150.	4.1	9
107	Who gains clinical benefit from using insulin pump therapy? A qualitative study of the perceptions and views of health professionals involved in the Relative Effectiveness of Pumps over \langle sc \rangle MDI \langle /sc \rangle and Structured Education (\langle sc \rangle REPOSE \langle /sc \rangle) trial. Diabetic Medicine, 2016, 33, 243-251.	2.3	51
108	Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1346-1347.	2.2	6

#	ARTICLE	IF	CITATIONS
109	Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes. <i>Diabetic Medicine</i> , 2015, 32, 1453-1459.	2.3	49
110	Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia. <i>Diabetes Care</i> , 2015, 38, 1016-1029.	8.6	192
111	Outcomes for Adults with Type 1 Diabetes Referred with Severe Hypoglycaemia and/or Referred for Islet Transplantation to a Specialist Hypoglycaemia Service. <i>Hormone and Metabolic Research</i> , 2015, 47, 9-15.	1.5	14
112	Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2015, 38, 1592-1609.	8.6	119
113	Efficacy of Insulin Pump Therapy in Elderly Patients. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 364-365.	4.4	14
114	Modification of Human Islet Preparation: An Effective Approach to Improve Graft Outcome After Islet Transplantation?. <i>Hormone and Metabolic Research</i> , 2015, 47, 72-77.	1.5	4
115	Technology to Reduce Hypoglycemia. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 911-916.	2.2	8
116	Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 801-807.	4.4	33
117	Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 452-458.	4.4	26
118	Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patient—An Evidence-based Approach. <i>Current Diabetes Reports</i> , 2015, 15, 81.	4.2	20
119	Hes3 Is Expressed in the Adult Pancreatic Islet and Regulates Gene Expression, Cell Growth, and Insulin Release. <i>Journal of Biological Chemistry</i> , 2014, 289, 35503-35516.	3.4	13
120	Wired for Obesity?. <i>Diabetes</i> , 2014, 63, 4016-4017.	0.6	2
121	Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 175-190.	4.0	36
122	Home Urine C-Peptide Creatinine Ratio Can Be Used to Monitor Islet Transplant Function: Figure 1. <i>Diabetes Care</i> , 2014, 37, 1737-1740.	8.6	5
123	A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study. <i>Diabetes Care</i> , 2014, 37, 863-866.	8.6	85
124	Insulin pump therapy: a practical guide to optimising glycaemic control. <i>Practical Diabetes</i> , 2014, 31, 121.	0.3	7
125	Modern technologies for glucose monitoring and insulin replacement. <i>Medicine</i> , 2014, 42, 703-706.	0.4	0
126	Poorer glycaemic control in type 1 diabetes is associated with reduced self-management and poorer perceived health: A cross-sectional study. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 35-41.	2.8	19

#	ARTICLE	IF	CITATIONS
127	Hypoglycaemia in hospital: a preventable killer?. Diabetic Medicine, 2014, 31, 1151-1152.	2.3	3
128	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes and Endocrinology, 2014, 2, 701-709.	11.4	140
129	Continuous subcutaneous insulin infusion for type 2 diabetes. Lancet, The, 2014, 384, 1240-1242.	13.7	2
130	Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. Programme Grants for Applied Research, 2014, 2, 1-188.	1.0	28
131	Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations. American Journal of Transplantation, 2013, 13, 3236-3243.	4.7	55
132	Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 4160-4162.	8.6	139
133	Insulin Pump Therapy With Automated Insulin Suspension. JAMA - Journal of the American Medical Association, 2013, 310, 1235.	7.4	10
134	Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?. Diabetic Medicine, 2013, 30, 914-917.	2.3	18
135	Blood Glucose Pattern Management in Diabetes: Creating Order from Disorder. Journal of Diabetes Science and Technology, 2013, 7, 1575-1584.	2.2	24
136	Redesigning an intensive insulin service for patients with type 1 diabetes: a patient consultation exercise. Patient Preference and Adherence, 2013, 7, 471.	1.8	5
137	Islet cell transplantation: current status in the UK. Practical Diabetes, 2012, 29, 280-285.	0.3	4
138	Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5	2.2	20
139	Evaluating Rate of Change as an Index of Glycemic Variability, Using Continuous Glucose Monitoring Data. Diabetes Technology and Therapeutics, 2011, 13, 631-636.	4.4	37
140	Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes Technology and Therapeutics, 2011, 13, 921-928.	4.4	279
141	Hypoglycaemia: current management and controversies. Postgraduate Medical Journal, 2011, 87, 298-306.	1.8	40
142	Relationship Between Interstitial and Blood Glucose During Hypoglycemia in Subjects with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 1121-1127.	4.4	12
143	Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Figure 1. Diabetes Care, 2011, 34, 2023-2025.	8.6	170
144	Hypoglycaemia in the treatment of diabetes mellitus. , 2011, , 1849-1861.		0

#	ARTICLE	IF	CITATIONS
145	Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a Clinical Audit: Response to Graveling and Frier. <i>Diabetes Care</i> , 2010, 33, e16-e16.	8.6	0
146	Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. <i>Diabetic Medicine</i> , 2010, 27, 666-672.	2.3	75
147	Taking training into your own hands. <i>Clinical Medicine</i> , 2010, 10, 349-351.	1.9	2
148	Evolution and resolution of human brain perfusion responses to the stress of induced hypoglycemia. <i>NeuroImage</i> , 2010, 53, 584-592.	4.2	42
149	The use of technology to reduce hypoglycemia. <i>Pediatric Endocrinology Reviews</i> , 2010, 7 Suppl 3, 384-95.	1.2	1
150	Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a clinical audit. <i>Diabetes Care</i> , 2009, 32, 1196-1198.	8.6	97
151	Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin and sulphonylurea-treated Type 2 diabetes. <i>Diabetic Medicine</i> , 2009, 26, 665-672.	2.3	14
152	Continuous glucose monitoring in patients with insulinoma. <i>Clinical Endocrinology</i> , 2008, 68, 912-918.	2.4	38
153	Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. <i>Diabetologia</i> , 2007, 50, 1140-1147.	6.3	803
154	Review of dietary recommendations for diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2004, 65, S9-S15.	2.8	22
155	Methods of Assessment of Counterregulation to Hypoglycaemia. , 0, , 77-103.		0
156	Flash glucose monitoring: the story so far and the journey ahead. <i>BMJ Innovations</i> , 0, , bmjinnov-2021-000862.	1.7	3